Last reviewed · How we verify
NCT06235229: DURGA-3
A Study of GC012F in Patients With Relapsed/Refractory Multiple Myeloma
Phase 1, PHASE2 trial testing GC012F in Multiple Myeloma in 110 participants. Currently enrolling.
2 March 2026
Quick facts
| Lead sponsor | Gracell Biotechnologies (Shanghai) Co., Ltd. |
|---|---|
| Phase | Phase 1, PHASE2 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 110 |
| Start date | 26 December 2023 |
| Primary completion | 2 March 2026 |
| Estimated completion | 2 March 2026 |
| Sites | 10 locations across China |
Drugs / interventions tested
- GC012F
Conditions studied
- Multiple Myeloma — all drugs for Multiple Myeloma →
Sponsor
Gracell Biotechnologies (Shanghai) Co., Ltd. — full company profile →
Who can join
Adults 18 to 75, any sex, with Multiple Myeloma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is a single-arm, open-lable, phase I/II study to evaluate the efficacy and safety of GC012F in subjects with relapsed/refractory multiple myeloma.
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
Multiple myeloma: signaling pathways and targeted therapy.
Lu Q, Yang D, Li H, Niu T, et al · · 2024 · cited 50× · PMID 38961036 · DOI 10.1186/s43556-024-00188-w -
Mapping the cancer surface proteome in search of target antigens for immunotherapy.
Di Meo F, Kale B, Koomen JM, Perna F. · · 2024 · cited 8× · PMID 39068512 · DOI 10.1016/j.ymthe.2024.07.019 -
Mechanisms of Resistance to CAR T-Cells and How to Overcome Them.
Legato L, Bisio M, Fasano F, Benevolo Savelli C, et al · · 2025 · cited 3× · PMID 40981226 · DOI 10.3390/mps8050108
Verify or expand the search:
- PubMed search for NCT06235229
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Multiple Myeloma
Currently open trials in the same condition.
- NCT07200102 — Selinexor Maintenance Post CAR-T Cell Therapy for Multiple Myeloma · Phase 1 · recruiting
- NCT07340853 — CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma · Phase 1 · recruiting
- NCT07454382 — A Study of Elranatamab and Cyclophosphamide in People With Multiple Myeloma · Phase 2 · recruiting
- NCT07266441 — A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma · Phase 2 · recruiting
- NCT07258511 — A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With · Phase 3 · recruiting
Other Gracell Biotechnologies (Shanghai) Co., Ltd. trials
Trials by the same sponsor.
- NCT07250269 — Study of GC012F, CAR-T Therapy Targeting CD19 and BCMA in Chinese Participants With Relapsed or Refractory AL Amyloidosi · Phase 1 · recruiting
- NCT06530849 — A Study of GC012F Injection in Subjects With Refractory Systemic Lupus Erythematosus · Phase 1, PHASE2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06235229 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Gracell Biotechnologies (Shanghai) Co., Ltd.
- Last refreshed: 25 February 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06235229.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing